Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

and without type 2 diabetes 1.6.7 Offer atorvastatin 20 mg for the primary prevention of CVD to people who have a 10-year QRISK3 score of 10% or more. [May 2023] 1.6.8 Do not rule out treatment with atorvastatin 20 mg for the primary prevention of CVD just because the person's 10-year QRISK3 score is less than 10% if they have an informed preference for taking a statin or there is concern that risk may be underestimated. [May 2023] 1.6.9 For people aged 85 and older consider treatment with atorvastatin 20 mg. Be aware of factors that may make treatment inappropriate (see recommendations 1.5.1 and 1.5.2). [May 2023] Statin treatment for people with type 1 diabetes 1.6.10 Offer statin treatment for the primary prevention of CVD to adults with type 1 diabetes who: • are older than 40 years or • have had diabetes for more than 10 years or • have established nephropathy or • have other CVD risk factors. [May 2023] 1.6.11 Consider statin treatment for the primary prevention of CVD for people aged 18 to 40 with type 1 diabetes, including those who have had diabetes for 10 years or less. [May 2023, amended December 2023] 1.6.12 When
